The Gynecologic Oncology Group
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1970-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.gog.org
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Phase 2
Completed
- Conditions
- Uterine Corpus LeiomyosarcomaRecurrent Uterine Corpus Sarcoma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 51
- Registration Number
- NCT00031629
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva
Phase 3
Completed
- Conditions
- Vulvar Cancer
- Interventions
- Procedure: Sentinel lymph node mapping
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 515
- Registration Number
- NCT00003325
- Locations
- 🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸Harry & Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center, Baltimore, Maryland, United States
🇺🇸Tufts-NEMC Cancer Center, Boston, Massachusetts, United States
Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer
Phase 2
- Conditions
- Recurrent Uterine Corpus CarcinomaStage III Uterine Corpus Cancer AJCC v7Stage IV Uterine Corpus Cancer AJCC v7
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 67
- Registration Number
- NCT00006903
Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer
Phase 2
Completed
- Conditions
- Cervical Squamous Cell Carcinoma, Not Otherwise SpecifiedRecurrent Cervical Carcinoma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 27
- Registration Number
- NCT00041093
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus
Phase 3
Completed
- Conditions
- Stage I Uterine Corpus CancerStage I Uterine SarcomaStage II Uterine Corpus CancerStage II Uterine SarcomaEndometrial Adenocarcinoma
- Interventions
- Procedure: Laparoscopic SurgeryOther: Quality-of-Life AssessmentProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 2616
- Registration Number
- NCT00002706
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer
Phase 2
Completed
- Conditions
- Recurrent Cervical CarcinomaCervical AdenocarcinomaCervical Adenosquamous Carcinoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 21
- Registration Number
- NCT00039442
- Locations
- 🇺🇸
Gynecologic Oncology Group of Arizona, Phoenix, Arizona, United States
Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia
Phase 3
Completed
- Conditions
- Cervical Adenosquamous CarcinomaCervical Squamous Cell CarcinomaDrug ToxicityRadiation ToxicityStage III Cervical CancerCervical AdenocarcinomaStage IIB Cervical CancerAnemiaStage IVA Cervical Cancer
- Interventions
- Radiation: External Beam Radiation TherapyRadiation: Internal Radiation TherapyBiological: Epoetin Alfa
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 114
- Registration Number
- NCT00017004
- Locations
- 🇺🇸
Gynecologic Oncology Group of Arizona, Phoenix, Arizona, United States
CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase 2
Completed
- Conditions
- Primary Peritoneal CarcinomaRecurrent Ovarian Carcinoma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 78
- Registration Number
- NCT00045682
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath